Navigation Links
Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Date:12/7/2011

these options is not yet available," said Chuck Bramlage, chief executive officer for Pearl Therapeutics. "We believe GP MDI has the clinical profile to fill this treatment gap and become a best-in-class LAMA monotherapy. In addition, GP MDI is a key component of our combination bronchodilator PT003, which, pending the successful completion of our remaining Phase 2b studies, we expect to advance into Phase 3 trials in 2012."

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment.

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing inhaled combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting
'/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
2. Anthera Announces Last Patient Enrolled in PEARL-SC Study
3. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
4. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
5. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
6. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
7. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
10. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
11. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... LEIDEN, Netherlands, March 8, 2011 Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) today announced that ... Subsequent Offering Period), Johnson & Johnson has acquired 98.89% ... treasury shares held by Crucell) and 98.93% of the issued ...
... 2011 Sequenom, Inc. (Nasdaq: SQNM ) today ... year ended December 31, 2010. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ... Total revenue for the fourth quarter of 2010 grew 28% ... quarter of 2009. The increase in revenue compared to the ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 2Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 3Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 4Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 5Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 6Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 8Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 9
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... ... Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. Collazo, ... Collazo, a 15 year veteran of helping drug, biologic and device firms reduce ...
(Date:7/30/2015)... ... 30, 2015 , ... World Patent Marketing, a vertically integrated ... that can help people during emergencies. , "The worldwide mobile health market revenue ... of World Patent Marketing. "Currently, there are about 97,000 mobile health apps available ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by ... , The decision will also allow him to spend more time in the office ... admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... most common cancers in the world. Although the prognosis ... survival rate for those who receive operative treatment is ... surgical intervention. However, many surviving patients might suffer from ... in their later life. , A research article ...
... agent for treatment of patients with chronic hepatitis ... monotherapy leads to the emergence of lamivudine-resistant hepatitis ... infected with HBV. Sensitive methods for early detection ... decisions in treating patients with HBV infection. , ...
... no shortages here , , WEDNESDAY, Jan. 16 (HealthDay News) ... the safety gaps in the U.S. food system. , ... one federal "superagency" to monitor food safety; beefing up ... the very least, giving the FDA the ability to ...
... builds on success in Eastern Washington, SPOKANE, Wash., ... establishing a larger presence in the Spokane community.,The new ... are already employed by WDS in Spokane. Eventually, the ... tremendous success with our customer service center in,Colville and ...
... Dr. Judah,Folkman, founder of the field of angiogenesis, died ... one of the thousands of lectures,that he gave to ... Folkman was founder and director of the Vascular Biology,Program ... Surgery,and Cell Biology at Harvard Medical School., When ...
... Expected Recurring ... ... Rate ... Stereotaxis, Inc. (Nasdaq:,STXS) today reported that due to the previously delayed European launch of,its partnered ...
Cached Medicine News:Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2Health News:U.S. Food Safety: Solutions at a Glance 2Health News:U.S. Food Safety: Solutions at a Glance 3Health News:Washington Dental Service Opens Larger Spokane Office 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 3Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 4Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 2Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 3Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 4
An Antiseptic - Antibacterial Cleanser that helps reduce bacteria that can potentially cause disease.Does not produce the systemic adverse effects associated with iodine or iodine by-products and is ...
... for professional degerming, pre-op and post-op ... combining quaternary and substituted phenolic active ... emollients and surfactants. Unprecedented efficacy on ... in 30 seconds. Techni-Care represents a ...
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... pouches are designed for individual application and ... used in nursing homes, home healthcare settings, ... other hospital departments. This unit dose pouch ... antiseptic, germicidal and cleansing agent. Hydrogen Peroxide's ...
Medicine Products: